Author:
Novitzky-Basso Igor,Craddock Charles
Subject
Hematology,General Medicine
Reference7 articles.
1. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia;Kantarjian;N Engl J Med,2002
2. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance;Kantarjian;Blood,2007
3. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase;Guilhot;Blood,2007
4. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety;Khoury;J Clin Oncol,2008
5. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP);Jabbour;J Clin Oncol,2008
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献